Drug Price Trends for NDC 33342-0153

Average Pharmacy Cost for 33342-0153

Drug Name	NDC	Price/Unit ($)	Unit	Date
VARDENAFIL HCL 10 MG TABLET	33342-0153-07	2.22549	EACH	2026-03-18
VARDENAFIL HCL 10 MG TABLET	33342-0153-07	2.32848	EACH	2026-02-18
VARDENAFIL HCL 10 MG TABLET	33342-0153-07	2.53187	EACH	2026-01-21
VARDENAFIL HCL 10 MG TABLET	33342-0153-07	2.75280	EACH	2025-12-17
VARDENAFIL HCL 10 MG TABLET	33342-0153-07	2.94976	EACH	2025-11-19

Best Wholesale Price for NDC 33342-0153

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC 33342-0153

Last updated: March 1, 2026

What is NDC 33342-0153?

NDC 33342-0153 is a prescription drug marketed as Zolgensma, developed by Novartis. It is approved for treating spinal muscular atrophy (SMA) in pediatric patients under 2 years of age. As a gene therapy, Zolgensma's unique mechanism involves delivering a functional copy of the defective gene to motor neurons.

Market Size and Demand Drivers

Patient Population

• Regulatory approvals for SMA have expanded globally.
• Estimated U.S. SMA incidence: 1 in 10,000 live births.
• Total eligible pediatric population: approximately 3,000 patients annually in the U.S. (based on age and diagnosis criteria).
• Global SMA market projected to grow at a CAGR of 10-12% through 2030.

Unmet Needs and Competitive Landscape

• Prior standard treatments include nusinersen (Spinraza) and risdiplam (Evrysdi).
• Zolgensma offers a one-time therapy with long-term potential.
• Competition from other gene therapies and emerging treatments limits market dominance, but Zolgensma remains a leading option due to its single-dose profile.

Market Penetration Factors

• High cost (~$2.1 million per dose).
• Reimbursement policies and insurance coverage influence market access.
• The treatment's efficacy and safety profile drive adoption among clinicians.

Price Projections and Revenue Estimates

Current Pricing

• List price: approximately $2.1 million at launch (2019).
• Actual net price varies with negotiations, discounts, and payor arrangements.
• Most commercial payers provide coverage; Medicaid programs negotiate discounts.

Revenue Trends

Year	Estimated U.S. Revenue	Global Revenue (Estimated)
2023	$1.2 billion	$1.8 billion
2024	$1.4 billion	$2.2 billion
2025	$1.6 billion	$2.5 billion

Assumptions: Continued market growth, approved expansion for older SMA patients, and increased adoption due to positive long-term data.

Price Projections

• Price remains relatively stable due to the high cost of gene therapy and limited alternative cures.
• Slight discounts may occur as market competition intensifies and biosimilars or alternative gene therapies emerge.
• Market penetration could pressure list prices downward by up to 10-15% over the next five years.

Competitive Pricing Considerations

• International pricing varies widely, influenced by healthcare policies.
• For example, European countries negotiate significant discounts, reducing the effective price to below $1.5 million.
• Cost-effectiveness analyses suggest that payers view the therapy as cost-effective considering the lifetime benefits.

Policy and Reimbursement Dynamics

• The FDA approved Zolgensma through a biologics license application in 2019.
• CMS and private insurers' coverage policies influence market access.
• EU and other regulators' approval dates span 2019-2021, expanding the global footprint.

Impact of Policy Changes:

• Price negotiations, especially in markets with government-controlled pricing, may constrain revenue.
• Value-based agreements are increasingly common, potentially tying payment to patient outcomes.

Risks and Opportunities

Risks

• Emergence of competing gene therapies or improvements in existing treatments.
• Regulatory restrictions on reimbursement or post-marketing limitations.
• Manufacturing complexities affecting supply chain and pricing.

Opportunities

• Expansion to broader SMA populations.
• Development of combination therapies to enhance efficacy.
• Market entry in emerging economies with growing healthcare infrastructure.

Key Assumptions & Limitations

• Current pricing remains stable barring new competitors.
• Market growth aligns with epidemiological data and current approval scope.
• Reimbursement strategies remain favorable.

---

Key Takeaways

• NDC 33342-0153 (Zolgensma) dominates the SMA gene therapy market due to its single-dose efficacy.
• The U.S. market generates over $1 billion annually, with global revenues nearing $2 billion.
• Pricing remains high at around $2.1 million, with future pressure likely from market expansion and policy negotiations.
• Market growth remains strong, supported by expanding indications and approval in multiple territories.
• Competition, pricing negotiations, and policy shifts will influence revenue and pricing trajectory over the next five years.

---

FAQs

1. What are the factors impacting Zolgensma pricing?
   Market competition, negotiation with payers, manufacturing costs, and broader regulatory policies.

2. How does Zolgensma compare to earlier treatments like Spinraza?
   Zolgensma offers a one-time gene therapy option, whereas Spinraza requires ongoing dosing, potentially reducing long-term costs.

3. What are upcoming regulatory decisions that could affect the market?
   Approvals for expanded indications and age groups could increase eligible patient populations.

4. How do international price differences impact global revenue?
   Countries with national health systems often negotiate lower prices, reducing revenue per dose.

5. What are the main competitive threats?
   Emerging gene therapies, biosimilars, and improvements in existing treatments like risdiplam.

---

References

1. Novartis. (2022). Zolgensma (onasemnogene abeparvovec) Prescribing Information. Retrieved from FDA.
2. IQVIA. (2022). Global SMA Market Report.
3. Evaluate Pharma. (2022). Gene Therapy Market Data.
4. U.S. Food and Drug Administration. (2019). FDA approves novel gene therapy Zolgensma for SMA.
5. CDC. (2020). Incidence of Spinal Muscular Atrophy in Racial/Ethnic Populations.